LivaNova Cash Flow Statement
NASDAQ: LIVNHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
LivaNova free cash flow
In fiscal 2025, LivaNova generated $254.3 million of operating cash flow and spent $81.0 million on capital expenditures. That left free cash flow of $173.3 million, a free-cash-flow margin of 12.5% of revenue. Free cash flow was up 27.5% from the prior year's $135.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
LivaNova cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -242.47M | 63.23M | 17.55M | -86.25M | -135.82M | -348.82M | -157.64M | -189.40M | -25.09M | -62.79M |
| Net Income growth (YoY) | -483.45% | +260.39% | — | — | — | — | — | — | — | -208.54% |
| Depreciation & Amortization | 28.56M | 25.10M | 24.74M | 22.37M | 24.54M | 29.03M | 30.32M | 32.75M | 37.05M | 85.36M |
| Stock-Based Compensation | 36.29M | 33.93M | 36.35M | 44.81M | 40.56M | 35.09M | 32.55M | 26.92M | 19.06M | 19.57M |
| Change in Working Capital | 22.54M | 2.66M | -42.04M | -23.00M | 12.87M | 24.59M | -15.32M | 1.21M | -47.93M | -22.43M |
| Operating Cash Flow | 254.34M | 183.04M | 74.91M | 69.92M | 102.54M | -79.42M | -91.14M | 120.49M | 91.34M | 90.15M |
| Capital Expenditures | -81.05M | -47.11M | -34.98M | -26.52M | -25.48M | -35.02M | -24.69M | -37.19M | -32.93M | -38.36M |
| Investing Cash Flow | -72.91M | -48.16M | -40.33M | -38.41M | 36.90M | -41.84M | -41.29M | -120.56M | -52.85M | -44.52M |
| Share Repurchases | — | — | — | — | — | 0 | 0 | -50.00M | 0 | -54.49M |
| Debt Issued | 0 | 335.51M | 50.00M | 507.55M | 0 | 886.90M | 197.16M | 103.57M | 2.05M | 7.23M |
| Debt Repaid | -280.93M | -247.55M | -21.62M | -223.54M | -452.26M | -482.06M | -24.21M | -23.83M | -22.75M | -21.11M |
| Financing Cash Flow | -285.66M | 18.55M | 21.48M | 280.13M | -181.48M | 310.76M | 146.58M | -42.35M | 11.29M | -118.04M |
| Net Change in Cash | -88.00M | 145.68M | 62.25M | 307.63M | -44.84M | 191.69M | 13.93M | -46.41M | 53.83M | -72.82M |
| Free Cash Flow | 173.29M | 135.93M | 39.93M | 43.40M | 77.07M | -114.45M | -115.83M | 83.30M | 58.41M | 51.79M |
This table shows 10 annual periods of LivaNova's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LIVN's reporting calendar. What is a cash flow statement?